MA41216A - Synthèse totale de trioxacarcine dc-45-a2 et préparation d'analogues de trioxacarcine - Google Patents
Synthèse totale de trioxacarcine dc-45-a2 et préparation d'analogues de trioxacarcineInfo
- Publication number
- MA41216A MA41216A MA041216A MA41216A MA41216A MA 41216 A MA41216 A MA 41216A MA 041216 A MA041216 A MA 041216A MA 41216 A MA41216 A MA 41216A MA 41216 A MA41216 A MA 41216A
- Authority
- MA
- Morocco
- Prior art keywords
- trioxacarcin
- analogues
- preparation
- total synthesis
- synthesis
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 238000006257 total synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094662P | 2014-12-19 | 2014-12-19 | |
| US201562186128P | 2015-06-29 | 2015-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41216A true MA41216A (fr) | 2017-10-24 |
Family
ID=56127867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041216A MA41216A (fr) | 2014-12-19 | 2015-12-17 | Synthèse totale de trioxacarcine dc-45-a2 et préparation d'analogues de trioxacarcine |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10899773B2 (fr) |
| EP (1) | EP3233877A4 (fr) |
| JP (1) | JP2017537968A (fr) |
| KR (1) | KR20170122718A (fr) |
| CN (1) | CN107250144A (fr) |
| AU (1) | AU2015364347A1 (fr) |
| BR (1) | BR112017013194A2 (fr) |
| CA (1) | CA2970955A1 (fr) |
| CL (1) | CL2017001599A1 (fr) |
| CO (1) | CO2017007074A2 (fr) |
| CR (1) | CR20170331A (fr) |
| DO (1) | DOP2017000144A (fr) |
| EA (1) | EA201791388A1 (fr) |
| EC (1) | ECSP17046657A (fr) |
| GT (1) | GT201700139A (fr) |
| HK (1) | HK1243422A1 (fr) |
| IL (1) | IL252947A0 (fr) |
| MA (1) | MA41216A (fr) |
| MX (1) | MX2017008162A (fr) |
| PE (1) | PE20171787A1 (fr) |
| PH (1) | PH12017501147A1 (fr) |
| SG (1) | SG11201704935XA (fr) |
| WO (1) | WO2016100833A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210230178A1 (en) * | 2017-08-17 | 2021-07-29 | William Marsh Rice University | Trioxacarcin analogs and dimers as potent anticancer agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815995A (ja) | 1981-07-22 | 1983-01-29 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−４５−ａ↓１およびｄｃ−４５−ａ↓２ならびにそれらの製造法 |
| EP0157203A3 (fr) | 1984-04-04 | 1986-10-01 | American Cyanamid Company | Agents antitumoraux LL-D49194 alpha 1, LL-D49194 bêta 1, LL-D49194 bêta 2, LL-D49194 bêta 3, LL-D49194 gamma, LL-D49194 delta, LL-D49194 epsilon, LL-D49194 dzéta, LL-D49194 êta LL-D499194 oméga 1, LL-D49194 oméga 2 et LL-D49194 oméga 3 |
| JPS63135389A (ja) | 1986-11-26 | 1988-06-07 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−４５類の誘導体 |
| EP2550285B1 (fr) | 2010-03-22 | 2017-07-19 | President and Fellows of Harvard College | Trioxacarcines et utilisations de celles-ci |
| JP6408478B2 (ja) | 2012-11-26 | 2018-10-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | トリオキサカルシン、トリオキサカルシン−抗体複合体、およびその用途 |
-
2015
- 2015-12-17 MA MA041216A patent/MA41216A/fr unknown
- 2015-12-18 CN CN201580076346.2A patent/CN107250144A/zh active Pending
- 2015-12-18 MX MX2017008162A patent/MX2017008162A/es unknown
- 2015-12-18 CR CR20170331A patent/CR20170331A/es unknown
- 2015-12-18 EP EP15871176.2A patent/EP3233877A4/fr not_active Withdrawn
- 2015-12-18 WO PCT/US2015/066703 patent/WO2016100833A2/fr not_active Ceased
- 2015-12-18 EA EA201791388A patent/EA201791388A1/ru unknown
- 2015-12-18 KR KR1020177020092A patent/KR20170122718A/ko not_active Withdrawn
- 2015-12-18 BR BR112017013194-3A patent/BR112017013194A2/pt not_active Application Discontinuation
- 2015-12-18 SG SG11201704935XA patent/SG11201704935XA/en unknown
- 2015-12-18 JP JP2017532666A patent/JP2017537968A/ja not_active Withdrawn
- 2015-12-18 AU AU2015364347A patent/AU2015364347A1/en not_active Abandoned
- 2015-12-18 PE PE2017001101A patent/PE20171787A1/es unknown
- 2015-12-18 CA CA2970955A patent/CA2970955A1/fr not_active Abandoned
- 2015-12-18 US US15/537,319 patent/US10899773B2/en active Active
- 2015-12-18 HK HK18102899.8A patent/HK1243422A1/zh unknown
-
2017
- 2017-06-15 IL IL252947A patent/IL252947A0/en unknown
- 2017-06-19 PH PH12017501147A patent/PH12017501147A1/en unknown
- 2017-06-19 CL CL2017001599A patent/CL2017001599A1/es unknown
- 2017-06-19 GT GT201700139A patent/GT201700139A/es unknown
- 2017-06-19 DO DO2017000144A patent/DOP2017000144A/es unknown
- 2017-07-14 CO CONC2017/0007074A patent/CO2017007074A2/es unknown
- 2017-07-19 EC ECIEPI201746657A patent/ECSP17046657A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3233877A2 (fr) | 2017-10-25 |
| WO2016100833A3 (fr) | 2017-01-05 |
| GT201700139A (es) | 2018-10-24 |
| AU2015364347A1 (en) | 2017-07-13 |
| BR112017013194A2 (pt) | 2018-01-02 |
| HK1243422A1 (zh) | 2018-07-13 |
| US20190023717A1 (en) | 2019-01-24 |
| CA2970955A1 (fr) | 2016-06-23 |
| US10899773B2 (en) | 2021-01-26 |
| DOP2017000144A (es) | 2017-09-29 |
| WO2016100833A2 (fr) | 2016-06-23 |
| IL252947A0 (en) | 2017-08-31 |
| KR20170122718A (ko) | 2017-11-06 |
| EP3233877A4 (fr) | 2018-10-17 |
| CO2017007074A2 (es) | 2017-10-20 |
| CR20170331A (es) | 2017-11-17 |
| MX2017008162A (es) | 2018-03-06 |
| PH12017501147A1 (en) | 2018-03-05 |
| PE20171787A1 (es) | 2017-12-28 |
| ECSP17046657A (es) | 2019-03-29 |
| EA201791388A1 (ru) | 2017-11-30 |
| CL2017001599A1 (es) | 2018-11-09 |
| CN107250144A (zh) | 2017-10-13 |
| SG11201704935XA (en) | 2017-07-28 |
| JP2017537968A (ja) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46180A (fr) | Analogues de l'amyline | |
| EP3302275A4 (fr) | Indication d'états physiologiques selon la sudation | |
| EP3174874A4 (fr) | Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants | |
| HUE055458T2 (hu) | Kompozíciók és módszerek 5'-Cap RNS-ek szintézisére | |
| ZA201703834B (en) | Oral care compositions and methods of use | |
| EP3271352A4 (fr) | Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci | |
| MA49715A (fr) | Oligomères et conjugués d'oligomères | |
| GB201500314D0 (en) | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension | |
| EP3160970A4 (fr) | Synthèse d'analogues d'halochondrines et leurs utilisations | |
| IL280690A (en) | Pharmaceutical preparations that include DGLA and their use | |
| PT3380525T (pt) | Formulações farmacêuticas e métodos que as utilizam | |
| EP3357485A4 (fr) | Cosmétique d'écran solaire | |
| EP3347334A4 (fr) | Déshydrohalogénation d'hydrochlorofluorocarbones | |
| EP3394099A4 (fr) | Formulations d'anticorps anti-il-10 modifiés | |
| EP3393459A4 (fr) | Compositions de nanoémulsion de fluorocarbure et procédés de préparation et d'utilisation associés | |
| ZA201801015B (en) | Oral care compositions and methods of using the compositions | |
| EP3407974A4 (fr) | Analogues d'amlexanox | |
| EP3344280A4 (fr) | Formation d'os | |
| EP3357483A4 (fr) | Cosmétique d'écran solaire | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| DK3319980T3 (da) | Formuleringer til forbedring af virkningen af hydrofobe lægemidler | |
| EP3387469A4 (fr) | Détermination d'électrofaciès | |
| PT3236938T (pt) | Composições farmacêuticas aquosas tópicas orais de flurbiprofeno e dexpantenol | |
| IL258304A (en) | Oral care compounds and methods for using the compounds | |
| IL256919A (en) | Pharmaceutical compositions useful for the treatment of tissue injury |